HARVARD RESEARCHERS MAY HAVE discovered the cause of multiple sclerosis (MS). This progressive disease affects 2.8 million individuals worldwide, and there is no cure. In the...

The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

The little-talked-about or diagnosed syndrome may be more prevalent in healthcare than we know.

Disclosure: I own a fraction of a share of Eli Lilly stock. We live in a very exciting time! Alzheimer’s medications that are more promising...